Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Phase of Trial: Phase III
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Plaque psoriasis
- Focus Registrational; Therapeutic Use
- Acronyms VOLTAIRE-PSO
- Sponsors Boehringer Ingelheim
- 10 Jan 2018 Status changed from active, no longer recruiting to completed.
- 06 Nov 2017 Planned End Date changed from 30 Sep 2017 to 14 Dec 2017.
- 24 May 2017 Status changed from recruiting to active, no longer recruiting.